|
|
|
|
|
|
|
Specialty Medications – Choosing the Right Strategic Partners to Support all Steps in the Journey from Discovery Through Commercialization discusses challenges in improving trial design, patient recruitment and enrollment in the specialty drug development process.
Download our white paper to learn more about removing barriers to streamline your clinical research process and gain access to qualified patient populations.
Improving trial design, patient recruitment and enrollment
To address critical unmet medical need, specialty medications are typically developed to target relatively small, highly focused patient populations. Such narrow focus is often driven by the fact that the therapy is either targeting a small overall patient cohort or that the therapy has a particular mechanism of action.
The clinical development team needs to confirm the current treatments used and their frequency to determine the most appropriate comparator and to meet their global commercialization needs. Such efforts can be streamlined by working with trusted third-party partners that have robust insight into treatment utilization across the different settings of care and access to up-to-date information that may impact the inclusion and exclusion criteria of each study required.
To support trial enrollment, developers of most specialty medications must turn to community-based specialty practices, where the majority of these patients are currently being treated.
|
|
|
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Applied Clinical Trials, an MJH Life Sciences™ brand. You are on the mailing list as %%emailaddress%%.
|
|
|
